Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $1,685,500.00 in Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 50,000 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $33.71, for a total transaction of $1,685,500.00. Following the sale, the director now directly owns 2,516,701 shares in the company, valued at approximately $84,837,990.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Gregory Bailey also recently made the following trade(s):

  • On Monday, January 22nd, Gregory Bailey sold 49,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $30.76, for a total transaction of $1,507,240.00.
  • On Tuesday, January 16th, Gregory Bailey sold 40,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $26.52, for a total transaction of $1,060,800.00.
  • On Thursday, January 4th, Gregory Bailey sold 50,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $28.71, for a total transaction of $1,435,500.00.
  • On Wednesday, December 20th, Gregory Bailey sold 39,430 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $26.31, for a total transaction of $1,037,403.30.
  • On Thursday, November 30th, Gregory Bailey sold 9,970 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $25.48, for a total transaction of $254,035.60.
  • On Friday, November 24th, Gregory Bailey sold 600 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $26.02, for a total transaction of $15,612.00.
  • On Monday, November 27th, Gregory Bailey sold 20,600 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $25.92, for a total transaction of $533,952.00.

Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) opened at $32.06 on Monday. Biohaven Pharmaceutical Holding Co Ltd has a fifty-two week low of $17.00 and a fifty-two week high of $39.51.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($1.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. equities analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -6.4 earnings per share for the current fiscal year.

BHVN has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. BidaskClub lowered shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, October 27th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective on shares of Biohaven Pharmaceutical in a report on Wednesday, November 15th. Piper Jaffray Companies set a $48.00 price objective on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a report on Monday, December 11th. Finally, Canaccord Genuity began coverage on shares of Biohaven Pharmaceutical in a report on Friday, December 15th. They set a “buy” rating and a $30.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. Biohaven Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $36.14.

Institutional investors have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in Biohaven Pharmaceutical in the 3rd quarter worth $119,000. Nationwide Fund Advisors bought a new stake in Biohaven Pharmaceutical during the third quarter worth about $214,000. American International Group Inc. bought a new stake in Biohaven Pharmaceutical during the third quarter worth about $251,000. State of Wisconsin Investment Board purchased a new position in Biohaven Pharmaceutical in the third quarter worth about $262,000. Finally, Susquehanna International Group LLP purchased a new position in Biohaven Pharmaceutical in the third quarter worth about $302,000. 47.76% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $1,685,500.00 in Stock” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/05/insider-selling-biohaven-pharmaceutical-holding-co-ltd-bhvn-director-sells-1685500-00-in-stock.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply